I know that this is paid for but its worth considering:
Feature: BioCurex exposes itself and turns the corner.
There’s no argument that the combination of crappy markets and corporate challenges have roiled the share price of cancer detection concern BioCurex (BOCX.PK). Now, with its corporate filings up to date, a successful road trip completed to expose its technologies to high profile potential partners and collaborators in the US and Europe (release below) as well as using its best efforts to return the shares to the NASDAQ Bulletin Board ASAP, risk oriented investors might be wise to have another look.
BioCurex is undoubtedly a long-term play. That said, as a result of the initiatives that the company is undertaking to attract potential licensees and research collaborators, it appears to be getting much closer to bearing fruit in the not too distant future.
We believe, that given that potential, risk oriented investors should begin or continue to accumulate the shares at these severely depressed levels. Over the next 6-12 months even a couple of small licensing deals could have a major impact on the BioCurex share price.
As you can readily see by the chart, the share price has been in a relatively profound decline since the stock was relegated to the pink sheets in April. The good news is that the shares have completely retraced their March-April run and, as well, have filled in the April 2nd gap.
Enough, already…
We feel that the selling—and perhaps shorting-- has been overdone and once the shares return, hopefully soon, to the OTCBB, the company should enjoy a renaissance among investors. The stigma--as well as the lack of reasonable trading of its shares while on the pink sheets-- has certainly taken its toll.
Not to mention the fact that the overall markets both in smallcaps and biotech basically suck—at least for the present. But, as we have said before, therein lies opportunity looking out to the late summer and fall as, we believe, represents the timing for a more robust smallcap market.
The Amex Biotech index has declined from 567 in April to just below 500 today—a level it last found itself at the end of 2003. The index has been range-bound for the last few months. A break above 525 would signal a new up-leg. A break below 485 would mean a short-term breakdown. Obviously we would like to see the former. Keep an eye—as we will—on this index.
In case you’ve missed the point
Let’s be clear here. We believe that BioCurex represents amazing potential for establishing a new way—a cheaper, easier, non-invasive way—of detecting cancer. There are no significant revenues as yet. Are the shares going to rise tomorrow or next month? Perhaps, but given the state of the markets and the rate at which investors are eschewing smallcaps, most companies, including BioCurex, are happy—as would investors—to merely idle for the moment.
However, as with any smallcap in its formative stages, which is obviously where BioCurex finds itself, the risk is in not having at least a modest long-term position. The leverage for investors should BioCurex inks a licensing deal we feel is extremely compelling. It’s always hardest to wade into a stock at its most ugly. While there are always risks, that point, for the most part, is also when the most money is made by those risk-oriented smallcap investors who can stand the vagaries and volatility as young, exciting companies establish themselves.
One should also not dismiss the importance of today’s news from BioCurex. The presentation at these two prestigious conferences further expands BioCurex’s sphere of influence. Attendees are exactly the types of top-tier research institutions that will further validate its technology and pharma companies that are potential licensees of BioCurex’s products. As large as that sphere seems, I’m sure that it is actually relatively small when discussion of new and exciting technologies ensues.
Great Oaks from little acorns grow.
Virtually every biotech company once found itself where BioCurex is today. In 1995 Imclone (NASDAQ: IMCL) traded for pennies. I’ll bet no one wanted it then. Today? Martha notwithstanding, it’s $80 bucks a share. There are lots more. Yes, and some have failed. The point? Those investors who bought the vision prior to the reality have a much greater chance of doing very nicely, thank you.
We brought this company to the readership at 17 cents last October—a read for background or as a refresher may be a good idea. It’s been a wild ride since as the shares moved from sub 20 cents then to $3.90 in April. Ironically, if one had bought the shares off of our initial trading alert, even at 50 odd cents you’d still be sitting on a triple.
We believe that for BioCurex the corner has been turned. While the shares could go lower—as could any stock in this market—the challenges seem to be behind this cutting edge cancer detection company.
PRESS RELEASE
BioCurex presentations attract significant scientific and corporate interest.
RICHMOND, British Columbia, July 14, 2004. -- BioCurex Inc. (BOCX.PK) - News BioCurex is pleased to provide an update on its presentations to the cancer community.
In the past 3 weeks BioCurex has presented results on its blood test (Serum-RECAF™) for cancer detection at the Early Diagnosis Research Network (EDRN), an initiative of the U.S. National Cancer Institute and at the annual meeting of the ISOBM, a prestigious international scientific society dedicated, for the past 32 years, to the detection of cancer markers.
Dr. Moro, President and CEO stated: “Our results were very well received and we were approached by numerous scientists interested in collaborating with us to define RECAF as a marker to detect a variety of cancers. We are now developing these international collaborations, which include groups from high profile institutions in the USA as well as international interest from The Netherlands, Germany and Spain.
Further, Dr. Taketa’s group in Japan, who also presented highly specific and sensitive results using Histo-RECAFTM for stomach cancer detection, will expand their project to include other types of cancers.”
Biocurex is providing the test kits and each group will then study the expression of RECAF in a particular type of cancer. Some of the tests may take place in BioCurex facilities, in which case the samples will be strictly encoded in a “blind test” to ensure that BioCurex scientists do not know the diagnosis until they have provided the results to the external investigator. These significant collaborations will not only provide additional validation from independent laboratories, but also allow a more effective and efficient method to study thousands of samples of many types of cancer. The information will be valuable in targeting our test to achieve the highest penetration of the technology in the marketplace.
BioCurex was also approached by four dominant companies in the industry at the congresses. In the upcoming weeks, BioCurex will be structuring several programs by which these companies will provide us with encoded samples in order to confidentially validate our claims in unbiased “blind” tests. This procedure is a common and necessary step in the process of licensing any new biotechnology.
Subsequently, BioCurex might hopes to establish a research alliance with one or more of these companies in order to modify the test for their specific analytic method as a preamble to a possible licensing agreement.
Dr. Moro commented, “In addition to the interest expressed by scientists, I was very pleased to note significant amounts of interest on behalf of major companies who contacted us. We are in the process of carefully studying their proposals. We are anxious to strike one or more licensing deals, but at the same time, the decisions we will make in the near future will dictate our revenues for many years to come. Thus, we want to do it right.”
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB: BOCX), visit our website at www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
Contact:
Ricardo Moro
BioCurex, Inc.
Tel: (604)207-9150
News 
Market Data 
Discover 
